Intus Bio

Overview
News
AI Drug Discovery?
Product stageSegments
Minimum Viable Product
?
AI SaaS | Biomarker Development
?

Intus Biosciences, formerly known as Shoreline Biome, specializes in advanced microbiome research and testing technologies. The company's flagship product is the Titan-1 platform, which combines patented assays and proprietary analysis tools to generate high-accuracy, high-resolution strain-level data on microbiomes. Titan-1 is designed to identify and track bacterial strains, including novel ones, without the need for whole genome sequencing. It utilizes a unique 16S-ITS-23S amplicon approach to create bacterial strain "fingerprints" for identification and tracking.

The platform offers capabilities beyond traditional 16S and shotgun metagenomics approaches, providing detailed insights into microbiome composition. Intus Bio's technology is applied across various fields including health, agriculture, and environmental studies. The company provides research and commercial services to global pharmaceutical, diagnostic, and testing industries. In June 2023, Intus Bio acquired Pattern Genomics, enhancing its capabilities with additional machine learning tools for biomarker discovery and patient stratification across large datasets.

Intus Bio's services include organizing and conducting testing of biological samples, collecting health and nutrition data, arranging sample collection and testing, and providing synthesized insights to customers. The company aims to deliver results within four to six weeks of receiving samples, offering personalized insights to help customers understand and optimize their microbiome health.

Key customers and partnerships

Intus Bio collaborates with pharmaceutical and academic organizations to support drug development and biomarker discovery for therapeutic and diagnostic purposes. The company also partners with commercial laboratories that use its technology to assist patients in areas ranging from improving gut function to wound management. Intus Bio works with Avero Diagnostics, a medical pathology laboratory based in the US, to carry out the analysis of stool test kits for its gut function tests.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
400 Farmington Ave Farmington CT USA
Founded year:
2015
Employees:
11-50
IPO status:
Private
Total funding:
USD 4.2 mn
Last Funding:
USD 2.0 mn (Series Unknown; Jul 2024)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.